Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Infectious Disease

What's the Difference Between India Ink and CrAg Tests?

At a Glance

The India ink stain is a visual test that lets doctors quickly see cryptococcosis yeast in spinal fluid. The CrAg test is a highly sensitive biochemical test that detects invisible traces of the fungus in blood or spinal fluid. Doctors often use both tests together to ensure an accurate diagnosis.

When diagnosing cryptococcosis, doctors often order two distinct tests to evaluate the fluids in your body: an India ink stain and a Cryptococcal Antigen (CrAg) test. The India ink test is a rapid visual method performed on your spinal fluid to spot the characteristic “halo” of the yeast under a microscope for a quick initial look [1]. In contrast, the CrAg test is a modern, highly sensitive biochemical test (used on either blood or spinal fluid) that detects specific molecules shed by the fungus, identifying the infection even if the yeast cells aren’t visible [2][3].

(Note: Hearing that tests were run on your spinal fluid can be scary, as it means the fluid was obtained through a lumbar puncture, often called a “spinal tap.” Testing this fluid is essential because cryptococcosis can be a severe infection that affects the central nervous system, and doctors need a direct look at what is happening around your brain and spine to treat you effectively.)

The India Ink Stain: A Visual Snapshot

The India ink stain is a traditional laboratory technique that relies on directly visualizing the fungus in your spinal fluid [4][1]. Cryptococcus yeast cells are surrounded by a thick, protective outer layer called a capsule. When India ink is added to the fluid sample, the ink particles cannot penetrate this capsule. Under a microscope, this creates a dark background with bright, clear “halos” surrounding the yeast cells, allowing the technician to see the organism immediately [4][1].

While it provides immediate visual proof of the infection, the India ink test has a significant limitation: it requires a relatively large amount of the fungus to be present to be seen [5][6]. Because of this lower sensitivity (the ability of a test to correctly identify patients who have the disease), it can sometimes miss early infections or cases where the fungal burden is low [6][5].

The CrAg Test: Detecting Invisible Traces

The Cryptococcal Antigen (CrAg) test operates differently. Instead of looking for the whole yeast cell, this test looks for specific pieces of the fungus—specifically, a complex sugar (polysaccharide) called glucuronoxylomannan that the yeast sheds into your blood and spinal fluid [2][7].

The CrAg test is widely considered the cornerstone of modern cryptococcal diagnosis because it is highly sensitive and accurate [8]. It can detect the presence of the fungus even when the actual yeast cells are too few to be seen with an India ink stain or haven’t yet grown in a laboratory culture [3][5].

Why Did I Need Both Tests?

Seeing multiple tests in your medical chart for the same condition can be overwhelming, but it is a standard, thorough approach to diagnosing cryptococcosis [9]. Doctors use these tests together as a safety net to ensure nothing is missed, as their strengths and weaknesses perfectly balance each other:

  • Catching test errors: In rare, severe cases where the amount of fungus in the body is incredibly high, the massive amount of shed sugars can actually overwhelm the CrAg test, causing it to incorrectly show a negative result (a phenomenon called the “prozone effect”) [8][10]. In these specific instances, the India ink stain acts as a vital backup, easily revealing the high number of yeast cells under the microscope [8][11]. (If the lab suspects the prozone effect, they can also simply dilute the sample and run the CrAg test again to get an accurate result [12]).
  • Speed vs. Accuracy: Both tests can be rapid, but they provide different types of confirmation. The India ink stain confirms the physical presence of the organism’s structure, while the CrAg test ensures that even microscopic traces of the fungal sugars are not missed [13][9][8].
  • Comprehensive Confirmation: Using multiple diagnostic methods increases the overall detection rate and gives your care team the most accurate picture of your condition to guide your treatment plan [9][14]. Going forward, your doctors may periodically repeat tests to monitor how well your antifungal treatments are working.

Common questions in this guide

Why do I need both an India ink stain and a CrAg test?
Doctors use both tests as a safety net to ensure no infection is missed. The CrAg test is highly sensitive for detecting invisible traces of the fungus, while the India ink stain acts as a vital visual backup in rare cases where the fungal amount is incredibly high.
What is an India ink stain?
An India ink stain is a traditional laboratory technique that adds dark ink to your spinal fluid sample. The ink cannot penetrate the thick outer capsule of the yeast, creating a bright halo effect that lets technicians see the fungus immediately under a microscope.
What does the CrAg test look for?
The Cryptococcal Antigen (CrAg) test looks for specific complex sugars shed by the fungus into your blood and spinal fluid. It can detect the infection accurately even when yeast cells are too few to be seen visually or haven't yet grown in a lab culture.
Will I need a spinal tap for these tests?
Yes, diagnosing cryptococcosis often requires a lumbar puncture, or spinal tap, to collect spinal fluid. This is necessary because the infection can severely affect your brain and spine, and doctors need to directly evaluate this fluid to treat you effectively.
What is the prozone effect in a CrAg test?
The prozone effect happens in rare, severe cases where a massive amount of shed fungal sugars overwhelms the CrAg test, causing a false negative result. In these instances, doctors rely on the India ink stain or dilute the sample to get an accurate reading.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Did my CrAg test result show a specific 'titer' or number, and what does that tell us about the severity of my infection?
  2. 2.Are you monitoring my CrAg levels in my blood, spinal fluid, or both going forward?
  3. 3.Since both tests were ordered, did they both come back positive, and how does that influence the length of my treatment plan?
  4. 4.Do we need to repeat either of these tests to make sure the antifungal medication is effectively clearing the infection?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Capsule-Deficient Cryptococcal Meningitis: A Diagnostic Conundrum.

    Shende T, Singh G, Xess I, et al.

    Journal of global infectious diseases 2022; (14(4)):165-169 doi:10.4103/jgid.jgid_255_21.

    PMID: 36636299
  2. 2

    Development of SERS-based immunoassay for the detection of cryptococcosis biomarker.

    Jiang H, Liu C, Qu Q, et al.

    Analytical and bioanalytical chemistry 2022; (414(16)):4645-4654 doi:10.1007/s00216-022-04081-9.

    PMID: 35441260
  3. 3

    Current and emerging technologies to develop Point-of-Care Diagnostics in medical mycology.

    Matsuo T, Wurster S, Hoenigl M, Kontoyiannis DP

    Expert review of molecular diagnostics 2024; (24(9)):841-858 doi:10.1080/14737159.2024.2397515.

    PMID: 39294931
  4. 4

    Cryptococcal meningitis in people living with human immunodeficiency virus in Nepal: Perspectives from resource limited setting.

    Sharma S, Acharya J, Rijal N, et al.

    Mycoses 2023; (66(1)):47-51 doi:10.1111/myc.13526.

    PMID: 36067003
  5. 5

    Phasing out India ink: the case for the CrAg LFA in modern practice.

    Morjaria S, Iturralde D, Clarck B, Babady NE

    Microbiology spectrum 2026; (14(1)):e0153125 doi:10.1128/spectrum.01531-25.

    PMID: 41347782
  6. 6

    Development of a Multiplex qPCR to Detect and Identify Cryptococcus neoformans and Cryptococcus gattii.

    Ye WM, Zheng XQ, Zhong Y, et al.

    ACS omega 2025; (10(49)):61011-61019 doi:10.1021/acsomega.5c10285.

    PMID: 41427194
  7. 7

    Cross-Reacting Ustilago maydis Causing False-Positive Cryptococcal Antigen Test Results.

    Cheng MP, Nguyen TT, Parkes LO, et al.

    Journal of clinical microbiology 2017; (55(10)):3135-3137 doi:10.1128/JCM.00920-17.

    PMID: 28747366
  8. 8

    When the test lies: Fatal cryptococcosis and the prozone effect in advanced HIV infection.

    Costa M, Rodrigues P, Araújo B, et al.

    Diagnostic microbiology and infectious disease 2026; (116(3)):117512 doi:10.1016/j.diagmicrobio.2026.117512.

    PMID: 42302495
  9. 9

    Comparison of mNGS with conventional methods for diagnosis of cryptococcal meningitis: a retrospective study.

    Jiang ZJ, Hong JC, Lin BW, et al.

    Scientific reports 2025; (15(1)):3656 doi:10.1038/s41598-025-86481-2.

    PMID: 39880818
  10. 10

    Cryptococcal pneumonia and meningitis in a renal transplant recipient with a false negative serum cryptococcal antigen due to postzone phenomenon.

    Ware C, Meledathu S, Tariq Z, et al.

    IDCases 2023; (34()):e01898 doi:10.1016/j.idcr.2023.e01898.

    PMID: 37810462
  11. 11

    A diagnostic blind spot: false-negative IMMY CrAg LFA and CrAg SQ in an immunocompetent patient with Cryptococcus gattii meningitis.

    Supriya M, Joshi A, Pooja M, et al.

    Diagnostic microbiology and infectious disease 2026; (116(3)):117494 doi:10.1016/j.diagmicrobio.2026.117494.

    PMID: 42247753
  12. 12

    False-negative result of serum cryptococcal antigen lateral flow assay in an HIV-infected patient with culture-proven cryptococcaemia.

    Borges MASB, Araújo Filho JA, Soares RBA, et al.

    Medical mycology case reports 2019; (26()):64-66 doi:10.1016/j.mmcr.2019.10.009.

    PMID: 31737475
  13. 13

    Metagenomic next-generation sequencing for cryptococcal meningitis diagnosis: a single-center experience.

    Zhao Z, Zhang Y, Fu J, Yu L

    Frontiers in cellular and infection microbiology 2025; (15()):1626290 doi:10.3389/fcimb.2025.1626290.

    PMID: 41459152
  14. 14

    Clinical Characteristics and Risk Factors for Mortality in Cryptococcal Meningitis: Evidence From a Cohort Study.

    Wang F, Wang Y, He J, et al.

    Frontiers in neurology 2022; (13()):779435 doi:10.3389/fneur.2022.779435.

    PMID: 35572932

This page provides educational information about cryptococcosis diagnostic tests. It does not replace professional medical advice, and you should always consult your doctor to interpret your specific lab results.

Get notified when new evidence is published on Cryptococcosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.